HPWM
ALNY icon

High Point Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

High Point Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01K Hold
10
– – ﹤0.01% 239
2026
Q1 		$3.31K Hold
10
– – ﹤0.01% 239
2025
Q4 		$3.98K Buy
+10
New +$4.43K ﹤0.01% 228

Other funds holding ALNY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

High Point Wealth Management's ALNY Position: Q2 2026 in Review

High Point Wealth Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 10 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #239.

High Point Wealth Management first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.98K in Q4 2025. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • High Point Wealth Management held 10 shares of Alnylam Pharmaceuticals worth $3.01K as of Q2 2026.
  • High Point Wealth Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of High Point Wealth Management's portfolio in Q2 2026, its #239 holding.
  • High Point Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • High Point Wealth Management's Alnylam Pharmaceuticals position peaked at $3.98K in Q4 2025.
  • 365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on High Point Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.